Downregulation of EZH2 Inhibits Epithelial–Mesenchymal Transition in Enzalutamide-Resistant Prostate Cancer

Scientists investigated the levels of EZH2 and the altered pathways in public database which was comprised with primary and metastatic prostate cancer patient tumors.